A detailed history of Abrdn PLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Abrdn PLC holds 314,537 shares of EXEL stock, worth $10.5 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
314,537
Previous 557,805 43.61%
Holding current value
$10.5 Million
Previous $12.5 Million 34.88%
% of portfolio
0.02%
Previous 0.02%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

SELL
$21.96 - $27.6 $5.34 Million - $6.71 Million
-243,268 Reduced 43.61%
314,537 $8.16 Million
Q1 2024

May 08, 2024

SELL
$20.17 - $23.93 $2.2 Million - $2.61 Million
-109,032 Reduced 16.35%
557,805 $13.2 Million
Q4 2023

Jan 31, 2024

BUY
$19.25 - $24.13 $12.8 Million - $16.1 Million
666,837 New
666,837 $16 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $10.7B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Abrdn PLC Portfolio

Follow Abrdn PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Abrdn PLC, based on Form 13F filings with the SEC.

News

Stay updated on Abrdn PLC with notifications on news.